asa guidelines for glp 1 The 2023 position on GLP-1 receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on 🔸 Should GLP-1 RAs be

No, you cannot take tirzepatide twice a week

It feels like your bodys working against you, not with you

By tailoring each dose adjustment to the patient's specific progress and side effects, the guiding principle is to find the lowest effective dose that comfortably sustains long-term results, rather than rushing to the maximum dose in the shortest time possible

The distinction between evidence-based pharmaceutical GLP-1 medications and unregulated patch products is critical for patient safety and treatment efficacy

Fatigue is actually listed as a common adverse reaction in the Summary of Product Characteristics (SmPC) for some GLP-1 receptor agonists, particularly those used at higher doses for weight management such as semaglutide 2.4mg (Wegovy) and liraglutide 3mg (Saxenda)

Medical Contraindications These include a personal or family history of medullary thyroid carcinoma, a diagnosis of Multiple Endocrine Neoplasia syndrome type 2, or known hypersensitivity to semaglutide or other medication components